STOPP START Toolkit
Digoxin at a long-term dose >125microgram/day with impaired renal function (eGFR <50mL/minute) o increased risk of toxicity (e.g. nausea, diarrhoea, arrhythmias) levels can be taken (must be > 6 hours post dose) if there is a risk of toxicity and/or toxicity suspected Loop diuretic (e.g. furosemide, bumetanide)
Download STOPP START Toolkit
Information
Domain:
Source:
Link to this page:
Related documents
20 rhythm strips on Precourse Self-Assessment with the ...
www.enrollware.comR – Atrial 250-400 Vent: 70 - 150 P – None, Fs PRI – None QRS – 0.04-0.10 Regular or Irregular No Ps (called Fs) Saw tooth Atrial Fibrillation • Ischemic heart disease • Digoxin toxicity • CHF • MI • Mitral or Tricuspid valve disease RHY – Irregular R – Atrial 350-600 Vent. – Below 100 controlled Above 100 uncontrolled
Potentially Harmful Drugs in the Elderly: Beers List and More
fmda.orgDigoxin (Lanoxin) doses >0.125 mg/d except for atrial arrhythmias (B) Toxicity due to reduced renal clearance5 Dose reduction, with monitoring19 Disopyramide (Norpace) (B, C) Negative inotrope; anticholinergic; sudden death5,15 Depends on type of arrhythmia; for atrial fibrillation, digoxin, quinidine, procainamide, sotalol, flecainide15,27
Cardiac Dysrhythmia Overview to help with ACLS Precourse ...
keymedinfo.comR– Atrial 250–400 Vent: 70 - 150 P – none, F’s PRI – none QRS – 0.04 – 0.10 Irregular, no P’s (called F’s) Saw tooth Atrial Fibrillation ♥ Ischemic heart disease ♥ Dig toxicity ♥ CHF ♥ MI ♥ Mitral or Tricuspid valve disease RHY – Irregular R– atrial 350-600 Vent. – below 100 controlled, above 100 uncontrolled ...
Atrial Fibrillation Management of Acute Atrial ...
www.med.umich.edufor the acute care of patients with atrial fibrillation (AF) and atrial flutter (AFL) at the University of Michigan Health System. It is hoped that this standardization of care will result in improved patient ... Digoxin Second line rate control agent, primarily because it tends to exert its rate controlling effect at rest, less so with exercise.
Left Ventricular Assist Device - AnMed Health
anmedhealth.orgAnti-Arrythmics Amiodarone, Digoxin Prevention of abnormal heart electrical rhythms such as Atrial Fibrillation (A. fib), Ventricular Fibrillation (V. fib), Ventricualr Tachycardia (V. tach) Anti-Platlet Aspirin, Plavix Prevention of platelet build-up/aggregation on the LVAD pump
AGS 2019 BEERS Pocket-PRINTABLE - hgsitebuilder.com
files.hgsitebuilder.comDigoxin for first-line treatment of atrial fibrillation or of heart failure Avoid this rate control agent as first-line therapy for atrial fibrillation. Avoid as first-line therapy for heart failure. If used for atrial fibrillation or heart failure, avoid dosages >0.125 mg/d Use in atrial fibrillation: should not be used as a first-line agent
Amiodarone: Guidelines for Use and Monitoring - American ...
www.aafp.orgDec 01, 2003 · recurrent atrial fibrillation in patients for whom a rhythm-control strategy is chosen. When long-term amiodarone therapy is used, potential drug …
Adult tachycardia - Resus
www.resus.org.ukProbable atrial fibrillation: • Control rate with beta-blocker • Consider digoxin or amiodarone if evidence of heart failure •– Anticoagulate if duration > 48 h Vagal manoeuvres If ineffective: • Give Adenosine (if no pre-excitation) 6 mg rapid IV bolus – If unsuccessful, give 12 mg – If unsuccessful, give 18 mg • Monitor ECG
Advanced Cardiac Life Support (ACLS) Review WWW.RN.ORG®
www.rn.orgto digoxin and decrease serum digoxin level. They are used to treat digoxin toxicity. Dose: Based on the serum digoxin level or the amount of digoxin ingested. Give the dose IV over 30 minutes using a 22 micron filter. Adverse effects: Precipitation of heart failure, hypokalemia, rapid ventricular rate in patients with atrial fibrillation.
Summary Product Characteristics - SIMDAX
www.simdax.comSimdax infusion should be used cautiously in patients with tachycardia atrial fibrillation with rapid ventricular response or potentially lifethreatening mih at yh arr . s Experience with repeated administration of Simdax is limited. Experience with concomitant use of vasoactive agents, including inotropic agents (except di goxin), is limited.